BioMarin PharmaceuticalvsMerck & Company

BMRN and MRK stock compared: price, dividend, valuation and results, from SEC filings.

BMRN

BioMarin Pharmaceutical Inc.

$58.51

Value $11.3B

+0.90%
BMRN's page

MRK

Merck & Company, Inc.

$143.37

Value $354B

-0.75%
MRK's page

BioMarin Pharmaceutical (BMRN) has a market value of $11.3B and Merck & Company (MRK) $354B. Over the last year, with dividends, BMRN moved +6.9% and MRK +58.8%. Dividend yield: BMRN none, MRK 2.37%.

At a glance

The main figures of both. A bar only shows which number is larger, not which is better.

  • Market value

    BMRN$11.3B

    MRK$354B

    MRK is 32 times BMRN

  • Revenue, 12 months

    BMRN$3.7B

    MRK$67.4B

    MRK is 18 times BMRN

  • Net income, 12 months

    BMRN-$19M

    MRK$2.5B

  • Operating margin

    BMRN3.1%

    MRK–

  • ROIC

    BMRN1.1%

    MRK3.9%

    2.8 points apart

  • P/E

    BMRN–

    MRK144.5

  • Dividend yield

    BMRN0.0%

    MRK2.4%

    2.4 points apart

  • 5-year return

    BMRN-28.0%

    MRK+98.6%

    126.6 points apart

A fainter bar means a negative number. The 5-year return includes dividends.

The price over time

Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.

BMRN-28.0%

MRK+98.6%

10015020020222023202420252026
Returns by period
PeriodBMRNWith dividendsMRKWith dividends
1 year since November 14, 2025+6.9%Price +6.9%+58.8%Price +54.3%
3 years since November 17, 2023-33.1%-12.6% a yearPrice -33.1%+54.4%+15.6% a yearPrice +40.9%
5 years since November 16, 2021-28.0%-6.4% a yearPrice -28.0%+98.6%+14.7% a yearPrice +70.5%
10 years since November 17, 2016-35.5%-4.3% a yearPrice -35.5%+225.1%+12.5% a yearPrice +139.6%

Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.

Every figure

As on each company's page. A description, not a recommendation: no one figure says which is better.

BMRNBioMarin PharmaceuticalMRKMerck & Company

Valuation

BMRNMRK
Valuation
Price$58.51$143.37
Market value$11.3B$354B
Enterprise value (EV)$14.7B$399B
P/E–144.5
P/E, 5-year median–14.8
P/B1.87.9
EV/EBIT129.083.7
Free cash flow yield5.0%4.2%

Results and growth

BMRNMRK
Results and growth
Revenue, 12 months$3.7B$67.4B
Net income, 12 months-$19M$2.5B
Free cash flow, 12 months$558M$14.7B
Earnings per share, 12 months-$0.10$0.98
Revenue growth, year on year12.9%1.3%
Revenue growth a year, past+11.6%over 5 years+9.4%over 5 years
EPS growth a year, past-16.7%over 5 years+21.2%over 5 years

Margins and returns on capital

BMRNMRK
Margins and returns on capital
Gross margin75.9%71.8%
Operating margin3.1%–
Net margin-0.5%3.6%
ROIC1.1%3.9%
ROE-0.3%5.2%

Balance sheet

BMRNMRK
Balance sheet
Cash$736M$9.7B
Total debt$4.2B$53.8B
Net debt / EBITDA17.85.7
Interest cover0.9×2.4×

Dividends and buybacks

BMRNMRK
Dividends and buybacks
Dividend yield–2.4%
Dividend per share, 12 months–$3.40
Dividend growth a year, past–+5.8%over 5 years
Buyback yield–1.4%
Shareholder yield–3.8%

Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.

Questions: BMRN or MRK

Didn't find what you were looking for?

Ask us
Which is bigger, BioMarin Pharmaceutical or Merck & Company?

By market value, Merck & Company ($354B) is about 31.5 times BioMarin Pharmaceutical ($11.3B), at today's prices.

How did BMRN and MRK stock do over the last 10 years?

Since November 17, 2016, BMRN's price moved -35.5% and MRK's +139.6%. With dividends: BMRN -35.5% (-4.3% a year), MRK +225.1% (+12.5% a year). Past returns do not predict future ones.

Which pays the higher dividend, BMRN or MRK?

The dividend yield at today's price is none for BioMarin Pharmaceutical and 2.37% for Merck & Company. Over the last twelve months they paid – and $3.40 per share.

Which has the higher profit margins, BioMarin Pharmaceutical or Merck & Company?

Over the last twelve months, the net margin was -0.5% for BioMarin Pharmaceutical and 3.6% for Merck & Company, and the operating margin 3.1% and –. Revenue was $3.7B and $67.4B.

Which is the better investment, BioMarin Pharmaceutical or Merck & Company?

The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.

Other comparisons

With each of the two, and with the largest in its sector.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

Descriptive data from SEC filings and market prices.